 |
|
|
|
|
 |
Contents |
 |
|
|
|
|
|
|
|
|
|
|
|
|
|
* Residue conservation analysis
|
|
|
|
|
PDB id:
|
 |
|
 |
| Name: |
 |
Hydrolase
|
 |
|
Title:
|
 |
Calpain 1 proteolytic core inactivated by wr18(s,s), an epoxysuccinyl-type inhibitor.
|
|
Structure:
|
 |
Calpain-1 catalytic subunit. Chain: a. Fragment: calpain catalytic domain, residues 27-356. Synonym: calpain-1 large subunit, calcium-activated neutral proteinase 1, canp 1, calpain mu-type, mucanp, micromolar-calpain. Engineered: yes
|
|
Source:
|
 |
Rattus norvegicus. Norway rat. Organism_taxid: 10116. Gene: capn1, cls1. Expressed in: escherichia coli bl21. Expression_system_taxid: 511693.
|
|
Resolution:
|
 |
|
2.04Å
|
R-factor:
|
0.184
|
R-free:
|
0.251
|
|
|
Authors:
|
 |
D.Cuerrier,P.L.Davies,R.L.Campbell,T.Moldoveanu
|
Key ref:
|
 |
D.Cuerrier
et al.
(2007).
Development of calpain-specific inactivators by screening of positional scanning epoxide libraries.
J Biol Chem,
282,
9600-9611.
PubMed id:
DOI:
|
 |
|
Date:
|
 |
|
31-Oct-06
|
Release date:
|
09-Jan-07
|
|
|
|
|
|
PROCHECK
|
|
|
|
|
Headers
|
 |
|
|
References
|
|
|
|
|
|
|
|
|
|
P97571
(CAN1_RAT) -
Calpain-1 catalytic subunit
|
|
|
|
Seq: Struc:
|
 |
 |
 |
713 a.a.
322 a.a.
|
|
|
|
|
|
|
 |
 |
|
|
Key: |
 |
PfamA domain |
 |
 |
 |
Secondary structure |
 |
|
|
|
|
 |
|
 |
|
 |
|
|
Gene Ontology (GO) functional annotation
|
|
|
|
 |
 |
 |
|
 |
 |
 |
 |
|
 |
|
Cellular component
|
intracellular
|
1 term
|
 |
|
Biological process
|
proteolysis
|
1 term
|
 |
|
Biochemical function
|
cysteine-type endopeptidase activity
|
2 terms
|
 |
|
|
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
|
|
|
| |
|
DOI no:
|
J Biol Chem
282:9600-9611
(2007)
|
|
PubMed id:
|
|
|
|
|
| |
|
Development of calpain-specific inactivators by screening of positional scanning epoxide libraries.
|
|
D.Cuerrier,
T.Moldoveanu,
R.L.Campbell,
J.Kelly,
B.Yoruk,
S.H.Verhelst,
D.Greenbaum,
M.Bogyo,
P.L.Davies.
|
|
|
|
| |
ABSTRACT
|
|
|
| |
|
Calpains are calcium-dependent proteases that are required for numerous
intracellular processes but also play an important role in the development of
pathologies such as ischemic injury and neurodegeneration. Many current small
molecule calpain inhibitors also inhibit other cysteine proteases, including
cathepsins, and need improved selectivity. The specificity of inhibition of
several calpains and papain was profiled using synthetic positional scanning
libraries of epoxide-based compounds that target the active-site cysteine. These
peptidomimetic libraries probe the P4, P3, and P2 positions, display (S,S)- or
(R,R)-epoxide stereochemistries, and incorporate both natural and non-natural
amino acids. To facilitate library screening, an SDS-PAGE assay that measures
the extent of hydrolysis of an inactive recombinant m-calpain was developed.
Individual epoxide inhibitors were synthesized guided by calpain-specific
preferences observed from the profiles and tested for inhibition against
calpain. The most potent compounds were assayed for specificity against
cathepsins B, L, and K. Several compounds demonstrated high inhibition
specificity for calpains over cathepsins. The best of these inhibitors,
WRH(R,R), irreversibly inactivates m- and mu-calpain rapidly (k(2)/K(i) =
131,000 and 16,500 m(-1) s(-1), respectively) but behaves exclusively as a
reversible and less potent inhibitor toward the cathepsins. X-ray
crystallography of the proteolytic core of rat mu-calpain inactivated by the
epoxide compounds WR gamma-cyano-alpha-aminobutyric acid (S,S) and WR
allylglycine (R,R) reveals that the stereochemistry of the epoxide influences
positioning and orientation of the P2 residue, facilitating alternate
interactions within the S2 pocket. Moreover, the WR
gamma-cyano-alpha-aminobutyric acid (S,S)-complexed structure defines a novel
hydrogen-bonding site within the S2 pocket of calpains.
|
|
|
|
|
| |
Selected figure(s)
|
|
|
| |
 |
 |
|
 |
|
 |
Figure 7.
FIGURE 7. Crystal structures of µI–II inactivated
by WR18(S,S) and WR13(R,R). A and B, fitted electron density of
WR18(S,S) and WR13(R,R), respectively. The observed electron
density for the ligands is shown by an F[o] – F[c] (omit) map
calculated for the structures omitting the ligands and contoured
at 2 . C and D, stereo
images demonstrating the hydrogen bonds formed by WR18(S,S) and
WR13(R,R), respectively. All polar bonds shorter than 3.2
Å are shown by dashes. Carbon atoms of the polypeptide are
colored white, and water molecules are shown as red spheres. The
flexible P3-Arg and P4-Trp moieties of the ligands were omitted
for clarity. Arrows point to the hydrogen bond between WR18(S,S)
and a water molecule within the S2 pocket in C and to the
(R,R)-epoxide specific hydrogen bond between the P2 backbone
amide of WR13(R,R) and Gly-271 in D.
|
 |
Figure 8.
FIGURE 8. Structural overlap of three epoxide-derived
ligands. The overlap of WR18(S,S), WR13(R,R) and E-64 was
obtained by the structural alignment of the -carbons of the
polypeptide chain. The color scheme is as in Fig. 7, with carbon
atoms of E-64 in pink. The active site for the WR18(S,S) complex
is shown as a surface. Arrows point to the position of the -carbons
of the P2 residues. The flexible P3-Arg and P4-Trp moieties of
WR13(R,R) and WR18(S,S) were omitted for clarity.
|
 |
|
|
|
| |
The above figures are
reprinted
by permission from the ASBMB:
J Biol Chem
(2007,
282,
9600-9611)
copyright 2007.
|
|
| |
Figures were
selected
by an automated process.
|
|
|
|
|
 |
 |
|
 |
 |
 |
 |
 |
 |
 |
 |
 |
|
Literature references that cite this PDB file's key reference
|
|
 |
| |
PubMed id
|
 |
Reference
|
 |
|
|
|
 |
I.O.Donkor
(2011).
Calpain inhibitors: a survey of compounds reported in the patent and scientific literature.
|
| |
Expert Opin Ther Pat, 21,
601-636.
|
 |
|
|
|
|
 |
D.P.Schafer,
S.Jha,
F.Liu,
T.Akella,
L.D.McCullough,
and
M.N.Rasband
(2009).
Disruption of the axon initial segment cytoskeleton is a new mechanism for neuronal injury.
|
| |
J Neurosci, 29,
13242-13254.
|
 |
|
|
|
|
 |
C.G.Yu,
A.Joshi,
and
J.W.Geddes
(2008).
Intraspinal MDL28170 microinjection improves functional and pathological outcome following spinal cord injury.
|
| |
J Neurotrauma, 25,
833-840.
|
 |
|
|
|
|
 |
H.Y.Lee,
J.D.Morton,
L.J.Robertson,
J.D.McDermott,
R.Bickerstaffe,
A.D.Abell,
M.A.Jones,
J.M.Mehrtens,
and
J.M.Coxon
(2008).
Evaluation of a novel calpain inhibitor as a treatment for cataract.
|
| |
Clin Experiment Ophthalmol, 36,
852-860.
|
 |
|
|
|
|
 |
T.Moldoveanu,
K.Gehring,
and
D.R.Green
(2008).
Concerted multi-pronged attack by calpastatin to occlude the catalytic cleft of heterodimeric calpains.
|
| |
Nature, 456,
404-408.
|
 |
|
PDB code:
|
 |
|
|
 |
 |
|
The most recent references are shown first.
Citation data come partly from CiteXplore and partly
from an automated harvesting procedure. Note that this is likely to be
only a partial list as not all journals are covered by
either method. However, we are continually building up the citation data
so more and more references will be included with time.
Where a reference describes a PDB structure, the PDB
code is
shown on the right.
|
|